• 3′-Amino-ddATP: Identity, Mechanism and Evidence

  2026-10-16

  3′-Amino-2′,3′-dideoxyadenosine-5′-triphosphate is catalogued as a modified adenine nucleotide intended for molecular biology research. The supplier attributes chain termination to replacement of the 3′ hydroxyl group with an amino group, but the cited material provides no identity-matched study, quantitative incorporation data, enzyme-specific performance, or direct comparator evidence.

• Tibolone: Product Identity and Evidence Scope

  2026-10-16

  The APExBIO listing identifies Tibolone under SKU C4946, but the supplied product information does not provide a chemical description, mechanism, assay readout, or matched research evidence. Accordingly, the product can be discussed only as a named commercial entry; biological activity, measurement meaning, comparative performance, and clinical relevance remain undocumented in the available source.

• SpCas9 mRNA: Identity, Mechanism and Evidence Scope

  2026-10-15

  APExBIO describes SKU R1006 as ARCA-capped, polyadenylated SpCas9 mRNA containing 5mCTP and ψUTP, encoding Streptococcus pyogenes Cas9 with two nuclear localization signals and a C-terminal HA tag. The product information supports a conceptual role in guide-directed CRISPR-Cas9 genome editing, but it does not establish translation, editing efficiency, specificity, stability, immune effects, or performance in any particular biological model.

• Gardiquimod: A Source-Bounded TLR7 Overview

  2026-10-15

  APExBIO describes Gardiquimod as a synthetic imidazoquinoline TLR7 agonist that activates human TLR7 and induces interferon-α-associated innate immune signaling. The same description attributes antiviral, regulatory T-cell, and pancreatic cancer-cell effects to the compound, but the supplied materials contain no identity-matched research paper, effect sizes, sample numbers, or independent validation. These claims should therefore be treated as product-description evidence rather than established comparative pharmacology.

• When Context Changes What a Cholesterol Signal Means

  2026-10-14

  A Filipin III signal is not synonymous with total cellular cholesterol. In the PHMG pulmonary-fibrosis study, it functioned as one readout within a broader model of macrophage lipid dysregulation, and its interpretation depended on the molecular species, cell model, comparator and orthogonal measurements.

• Anti-MYH11 Antibody: Evidence Overview

  2026-10-14

  The available record identifies MA3848 as the Anti-MYH11 Rabbit Monoclonal Antibody supplied by APExBIO. No matched research paper or product description was provided, so its documented identity can be summarized, but application-specific performance, specificity, validation, and outcomes cannot be independently assessed.

• Haloprogin: What the 1970 Study Showed

  2026-10-13

  A source-grounded overview of Harrison and colleagues’ 1970 evaluation of Haloprogin, covering its comparative antifungal spectrum, topical guinea-pig findings, and the limits of translating early preclinical evidence to human treatment.

• AZD6482 and DM1: What the Evidence Shows

  2026-10-13

  The supplied DM1 study identifies HSP90-linked, differentiation-dependent regulation of DMPK RNA and RNA foci, but it does not evaluate AZD6482. Current evidence therefore supports a clear separation between findings on HSP90 and product-level claims about this PI3Kβ inhibitor, with no direct basis for inferring an effect on DM1 biology.

• Sodium Chloride B7288: Identity and Evidence Scope

  2026-10-12

  Sodium chloride (NaCl), listed by APExBIO as SKU B7288, is an inorganic salt described for conceptual use in aqueous buffer preparation, ionic-strength control, osmotic balance, and selected cell culture media contexts. No matched research paper or product-specific outcome evidence was provided, so applicability and performance claims remain limited.

• HNF4A-AS1 and Sorafenib Resistance in HCC

  2026-10-12

  This 2024 Theranostics study links reduced HNF4A-AS1 to sorafenib resistance in hepatocellular carcinoma through DECR1-associated lipid remodeling and weaker ferroptosis susceptibility. Its multi-model evidence is mechanistically suggestive but remains preclinical and does not establish a clinical biomarker or treatment.

• 1-Myristoylglycerophosphocholine: Evidence Boundaries

  2026-10-11

  A source-grounded overview distinguishing evidence for LysoPC-related fibrosis mechanisms from evidence specifically concerning 1-myristoylglycerophosphocholine (14:0 Lyso-PC).

• Ciclesonide: Evidence, Uses, and Research Limits

  2026-10-10

  Ciclesonide is a glucocorticoid prodrug used in respiratory pharmacology research, with reported conversion to the more potent metabolite desisobutyryl-ciclesonide. This overview compares its asthma-related evidence with a separate 2026 study of desonide-based ERAD degraders and explains why the compounds should not be treated as interchangeable.

• CREC Carbapenemase Genes: Transmission Evidence

  2026-10-09

  Chen et al. characterize carbapenemase-encoding genes, mobile genetic elements, resistance profiles, and strain relatedness in 54 carbapenem-resistant Enterobacter cloacae isolates from eight teaching hospitals in Guangdong. The study links frequent plasmid-associated blaNDM-1 with multidrug resistance and substantial transfer potential, while also showing why molecular findings should not be equated automatically with documented hospital transmission.

• Chlorambucil in Cancer Research: Evidence and Limits

  2026-10-09

  A source-grounded overview of Chlorambucil research, emphasizing nitrogen mustard biology, assay interpretation, conceptual applications, evidence quality, and limits on translating in vitro findings to clinical or cross-model conclusions.

• Dual-Action Inhibitors and p38α Dephosphorylation

  2026-10-08

  A 2024 bioRxiv preprint reports that three kinase inhibitors can do more than block p38α catalytic activity: they also increase WIP1-mediated dephosphorylation of the kinase activation loop. Biochemical and X-ray structural evidence supports a model in which inhibitor-stabilized activation-loop conformations expose the phospho-threonine, offering a mechanistic framework for designing more selective kinase-directed interventions.

8501 records 1/567 page Next 12345 下5页 Last page